China Aoxing Pharmaceutical Company (中国奥星药业) has received an SFDA production license for Isosorbide Mononitrate Injection, a vasodilator, for treatment of angina pectoris, myocardial infarction, chronic congestive heart failure, pulmonary hypertension and related coronary artery disease. China Aoxing, which focuses on pain medications, plans to begin selling its newest product to hospitals in the second half of 2009. More details...

Stock Symbol: (OTCBB: CAXG)